165 related articles for article (PubMed ID: 37635218)
21. RhoGDIβ affects HeLa cell spindle orientation following UVC irradiation.
Doi N; Kunimatsu Y; Fujiura K; Togari H; Minagi K; Nakaoji K; Hamada K; Temme A; Tatsuka M
J Cell Physiol; 2019 Sep; 234(9):15134-15146. PubMed ID: 30652309
[TBL] [Abstract][Full Text] [Related]
22. ZAK negatively regulates RhoGDIbeta-induced Rac1-mediated hypertrophic growth and cell migration.
Huang CY; Yang LC; Liu KY; Chang IC; Liao PH; Chou JI; Chou MY; Lin WW; Yang JJ
J Biomed Sci; 2009 Jun; 16(1):56. PubMed ID: 19538723
[TBL] [Abstract][Full Text] [Related]
23. Review: BBN as an urothelial carcinogen.
Vasconcelos-Nóbrega C; Colaço A; Lopes C; Oliveira PA
In Vivo; 2012; 26(4):727-39. PubMed ID: 22773588
[TBL] [Abstract][Full Text] [Related]
24. RhoGDIbeta-induced hypertrophic growth in H9c2 cells is negatively regulated by ZAK.
Huang CY; Yang LC; Liu KY; Liao PH; Chou JI; Chou MY; Lin WW; Yang JJ
J Biomed Sci; 2009 Jan; 16(1):11. PubMed ID: 19272173
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory effect of an aromatic retinoic acid analog on urinary bladder carcinogenesis in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Murasaki G; Miyata Y; Babaya K; Arai M; Fukushima S; Ito N
Gan; 1980 Jun; 71(3):333-40. PubMed ID: 7418979
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor mRNA levels as a biomarker for short-term N-butyl-N-(4-hydroxybutyl) nitrosamine-induced rat bladder carcinogenesis bioassay.
Wakui S; Mutou T; Takahashi H; Ikegami M; Wanibuchi H; Fukushima S
J Appl Toxicol; 2015 Feb; 35(2):181-90. PubMed ID: 24888239
[TBL] [Abstract][Full Text] [Related]
27. ISO, via Upregulating MiR-137 Transcription, Inhibits GSK3β-HSP70-MMP-2 Axis, Resulting in Attenuating Urothelial Cancer Invasion.
Guo X; Huang H; Jin H; Xu J; Risal S; Li J; Li X; Yan H; Zeng X; Xue L; Chen C; Huang C
Mol Ther Nucleic Acids; 2018 Sep; 12():337-349. PubMed ID: 30195772
[TBL] [Abstract][Full Text] [Related]
28. Apoptosis‑independent cleavage of RhoGDIβ at Asp19 during PMA‑stimulated differentiation of THP‑1 cells to macrophages.
Ota T; Jiang YS; Fujiwara M; Tatsuka M
Mol Med Rep; 2017 Apr; 15(4):1722-1726. PubMed ID: 28260067
[TBL] [Abstract][Full Text] [Related]
29. The carbonic anhydrase inhibitor acetazolamide inhibits urinary bladder cancers via suppression of β-catenin signaling.
Matsue T; Gi M; Shiota M; Tachibana H; Suzuki S; Fujioka M; Kakehashi A; Yamamoto T; Kato M; Uchida J; Wanibuchi H
Cancer Sci; 2022 Aug; 113(8):2642-2653. PubMed ID: 35723039
[TBL] [Abstract][Full Text] [Related]
30. Strain differences in N-butyl-N-(4-hydroxybutyl)nitrosamine bladder carcinogenesis in rats.
Nakanowatari J; Fukushima S; Imaida K; Ito N; Nagase S
Jpn J Cancer Res; 1988 Apr; 79(4):453-9. PubMed ID: 3133335
[TBL] [Abstract][Full Text] [Related]
31. Regulation of the prostaglandin pathway during development of invasive bladder cancer in mice.
Taylor JA; Ristau B; Bonnemaison M; Voznesensky OS; Hegde P; Kuchel GA; Pilbeam CC
Prostaglandins Other Lipid Mediat; 2009 Jan; 88(1-2):36-41. PubMed ID: 18834948
[TBL] [Abstract][Full Text] [Related]
32. [An experimental study on bladder carcinogenesis in dogs by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) and its urinary metabolites].
Morishita S; Hamami G; Kamidono S
Hinyokika Kiyo; 1989 Jan; 35(1):27-38. PubMed ID: 2729018
[TBL] [Abstract][Full Text] [Related]
33. The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice.
Degoricija M; Korac-Prlic J; Vilovic K; Ivanisevic T; Haupt B; Palada V; Petkovic M; Karaman I; Terzic J
J Transl Med; 2019 Nov; 17(1):394. PubMed ID: 31779626
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory effect of 13-cis-retinoic acid on urinary bladder carcinogenesis induced in C57BL/6 mice by N-butyl-N-(4-hydroxybutyl)-nitrosamine.
Becci PJ; Thompson HJ; Grubbs CJ; Squire RA; Brown CC; Sporn MB; Moon RC
Cancer Res; 1978 Dec; 38(12):4463-6. PubMed ID: 719631
[TBL] [Abstract][Full Text] [Related]
35. RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation.
Yang J; Platt LT; Maity B; Ahlers KE; Luo Z; Lin Z; Chakravarti B; Ibeawuchi SR; Askeland RW; Bondaruk J; Czerniak BA; Fisher RA
Oncotarget; 2016 Oct; 7(43):69159-69172. PubMed ID: 27713144
[TBL] [Abstract][Full Text] [Related]
36. Orally administered nicotine effects on rat urinary bladder proliferation and carcinogenesis.
Suzuki S; Cohen SM; Arnold LL; Kato H; Fuji S; Pennington KL; Nagayasu Y; Naiki-Ito A; Yamashita Y; Takahashi S
Toxicology; 2018 Apr; 398-399():31-40. PubMed ID: 29501575
[TBL] [Abstract][Full Text] [Related]
37. Carcinogenicity of N-nitrosamines related to N-butyl-N-(4-hydroxybutyl)nitrosamine and N,N,-dibutylnitrosamine in ACI/N rats.
Okada M; Suzuki E; Hashimoto Y
Gan; 1976 Dec; 67(6):825-34. PubMed ID: 191321
[TBL] [Abstract][Full Text] [Related]
38. Effect of lupeol on antioxidants and xenobiotic enzymes in N-Butyl-N-(4-hydroxybutyl) nitrosamine induced bladder carcinogenesis in experimental rats.
Prabhu B; Sivakumar A; Balakrishnan D; Sundaresan S
J Exp Ther Oncol; 2017 Sep; 11(2):139-416. PubMed ID: 28976137
[TBL] [Abstract][Full Text] [Related]
39. Monomethylarsonous acid produces irreversible events resulting in malignant transformation of a human bladder cell line following 12 weeks of low-level exposure.
Wnek SM; Jensen TJ; Severson PL; Futscher BW; Gandolfi AJ
Toxicol Sci; 2010 Jul; 116(1):44-57. PubMed ID: 20375083
[TBL] [Abstract][Full Text] [Related]
40.
Wakui S; Takahashi H; Muto T
Toxicol Pathol; 2022 Apr; 50(3):366-380. PubMed ID: 35045775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
